Philippe Huot-Marchand
31 works · 1,210 citations · h-index 8
Top works
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer
- A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study
- Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France
- The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
- Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
- Effectiveness of the Crizotinib Therapeutic Management Guide in Communicating Risks, and Recommended Actions to Minimize Risks, Among Physicians Prescribing Crizotinib in Europe
- P2.01-047 Intra- and Inter-Observer Reproducibility Study of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC) - The DREAM STUDY
- Oral treatment for mucopolysaccharidosis VI : Outcomes of the first phase IIa study with odiparcil
- Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
- A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) study
- Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment
- Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis)
- Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis
- Observational study of ferric carboxymaltose in France (OncoFer; interim analysis).
- 830-P: The Pan-PPAR Agonist Lanifibranor Improves Nonalcoholic Steatohepatitis (NASH) and Glycemic Control
- Correlation between severity of hepatic steatosis and markers of cardiometabolic health, and effect of lanifibranor therapy in patients with non-cirrhotic NASH
- The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change
- ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation (BRCAm) testing and counselling model for patients with ovarian cancer.
- ADOLESCENTS AND ADULTS WITH FONTAN CIRCULATION: BASELINE CHARACTERISTICS FROM THE PREPARE FONTAN REGISTRY